Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Neuroradiol J ; 37(2): 251-256, 2024 Apr.
Article in English | MEDLINE | ID: mdl-37385015

ABSTRACT

Eagle jugular syndrome is an uncommon condition caused by compression of an elongated styloid process onto the internal jugular vein. Its presentation is non-specific but may represent in severe clinical consequences including venous thrombosis and intracranial haemorrhage. Thorough understanding of local anatomy is important in understanding the pathogenesis and establishing the diagnosis. Our case reported here illustrates the use of multimodality imaging, including dynamic Computer tomography manoeuvre, in identifying the site of obstruction and guidance towards successful surgical treatment.


Subject(s)
Eagles , Intracranial Hypertension , Ossification, Heterotopic , Temporal Bone/abnormalities , Humans , Animals , Intracranial Hypertension/diagnostic imaging , Intracranial Hypertension/etiology , Intracranial Hypertension/surgery , Temporal Bone/diagnostic imaging , Temporal Bone/surgery , Multimodal Imaging
2.
Epilepsia Open ; 7(4): 570-577, 2022 12.
Article in English | MEDLINE | ID: mdl-35867810

ABSTRACT

OBJECTIVE: As Hong Kong faced the 5th wave of the COVID-19 pandemic, the facilitators and hurdles toward effective vaccination is important for healthcare professionals to understand the vaccination gap among patients with epilepsy. METHODS: A cross-sectional, pragmatic study of COVID-19 vaccination was performed at a tertiary epilepsy center with regards to patterns of vaccination and any unusually high rate of adverse events. Patients having recent visits at the epilepsy center (4 months) had their anonymized electronic linkage records examined 12 months after the inception of vaccination program for types of vaccines, seizure demographics, and adverse events following immunization (AEFI). RESULTS: A total of 200 patients with epilepsy and their anonymized data were analyzed. The vaccine uptake was approximately 60% of that of the general population. Twice as many patients with epilepsy chose to receive mRNA vaccine as compared with inactivated vaccine. The proportion of patients who kept up-to-date with all available dosing was 7%. Patients with epilepsy with genetic etiology were least likely to receive vaccination (13/38, 34%, P = .02). There was no unreasonably high rate of unacceptable side effects after vaccination among patients with epilepsy. Only 3 patients reported worsening of seizures without meeting the criteria for AEFI. Refractory epilepsy, allergy to antiseizure medications and elder age (≥65) did not confer any significant difference in vaccination patterns or adverse effects. SIGNIFICANCE: A vaccination gap exists among epilepsy patients which calls for actionable strategies for improving vaccine uptake, including education and outreach programs.


Subject(s)
COVID-19 , Drug-Related Side Effects and Adverse Reactions , Epilepsy , Vaccines , Humans , Aged , Cross-Sectional Studies , COVID-19 Vaccines/adverse effects , Pandemics/prevention & control , COVID-19/prevention & control , Hong Kong/epidemiology , Vaccination/adverse effects , Epilepsy/drug therapy , Epilepsy/complications , Seizures/etiology , Drug-Related Side Effects and Adverse Reactions/complications , Drug-Related Side Effects and Adverse Reactions/epidemiology , mRNA Vaccines
3.
Epileptic Disord ; 23(3): 500-505, 2021 Jun 01.
Article in English | MEDLINE | ID: mdl-34057410

ABSTRACT

Autoimmune encephalitis is increasingly recognised as a major cause of new-onset refractory status epilepticus. Early immunotherapy with agents such as methylprednisolone is recommended. Anakinra is an interleukin-1 receptor antagonist used for various inflammatory disorders. It has been used successfully in the treatment of febrile infection-related epilepsy syndrome in children and in one adult case. In this case report, we describe a case of super-refractory status epilepticus in a 38-year-old female due to autoimmune encephalitis who was treated successfully with anakinra after 16 weeks of therapeutic coma and failing multiple immunotherapies. Despite a prolonged period of therapeutic coma, this patient made a reasonable recovery with effective communication and ability to walk with assistance upon discharge. We propose that the successful treatment with anakinra in our case could be due to elevated inflammatory cytokines in the pathogenesis of autoimmune encephalitis, although we acknowledge that interleukin levels were unfortunately not available. We conclude that anakinra can be a valuable alternative option in patients with autoimmune encephalitis refractory to conventional immunotherapies.


Subject(s)
Encephalitis , Interleukin 1 Receptor Antagonist Protein/adverse effects , Status Epilepticus , Adult , Coma , Encephalitis/drug therapy , Female , Hashimoto Disease , Humans , Receptors, Interleukin-1 , Status Epilepticus/drug therapy , Status Epilepticus/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...